Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KB | Q9UBF8 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | CLK4 | Q9HAZ1 | 5/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | APEX1 | P27695 | 2/20 | 0.37 |
| ▸ | CASP7 | P55210 | 2/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29644502 | 1.00 | PI4KB (0.43) | PI4KBKDM4ESMN1; SMN2ALDH1A1RAB9A | |
| SCHEMBL29644484 | 0.84 | PI4KB (0.49) | PI4KB | |
| SCHEMBL21628161 | 0.84 | PI4KB (0.49) | PI4KB | |
| SCHEMBL23023809 | 0.83 | PI4KB (0.37) | PI4KBCLK4DYRK1ASMPD3 | |
| SCHEMBL21628164 | 0.81 | PI4KB (0.45) | PI4KBSMN1; SMN2RAB9ANPC1 | |
| SCHEMBL20528846 | 0.80 | PI4KB (0.42) | PI4KBSMPD3 | |
| SCHEMBL29644511 | 0.80 | PI4KB (0.42) | PI4KBSMPD3 | |
| SCHEMBL20528858 | 0.80 | PI4KB (0.54) | PI4KBKDM4ESMN1; SMN2ALDH1A1RAB9A | |
| SCHEMBL29644496 | 0.80 | PI4KB (0.54) | PI4KBKDM4ESMN1; SMN2ALDH1A1RAB9A | |
| SCHEMBL21628168 | 0.79 | PI4KB (0.46) | PI4KB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4028131-B1 | HETEROAROMATIC COMPOUNDS USEFUL IN THERAPY | CUROVIR AB (SE) | 2023-11-22 | — | — | EP | claimed |
| EP-4028131-A1 | HETEROAROMATIC COMPOUNDS USEFUL IN THERAPY | CUROVIR AB (SE) | 2022-07-20 | — | — | EP | claimed |
| EP-3606926-B1 | HETEROAROMATIC COMPOUNDS USEFUL IN THERAPY | CUROVIR AB (SE) | 2021-05-26 | — | — | EP | claimed |
| WO-2021032611-A1 | HETEROAROMATIC COMPOUNDS USEFUL IN THERAPY | CUROVIR AB (SE) | 2021-02-25 | — | — | WO | claimed |
| US-20200031833-A1 | HETEROAROMATIC COMPOUNDS USEFUL IN THERAPY | CUROVIR AB (SE) | 2020-01-30 | — | — | US | claimed |
| EP-4028131-B1 | HETEROAROMATIC COMPOUNDS USEFUL IN THERAPY | CUROVIR AB (SE) | 2023-11-22 | — | — | EP | disclosed |
| EP-4028131-B1 | HETEROAROMATIC COMPOUNDS USEFUL IN THERAPY | CUROVIR AB (SE) | 2023-11-22 | — | — | EP | disclosed |
| EP-3606926-B1 | HETEROAROMATIC COMPOUNDS USEFUL IN THERAPY | CUROVIR AB (SE) | 2021-05-26 | — | — | EP | disclosed |
| EP-3606926-B1 | HETEROAROMATIC COMPOUNDS USEFUL IN THERAPY | CUROVIR AB (SE) | 2021-05-26 | — | — | EP | disclosed |
| US-11001587-B2 | Substituted indazoles as phosphatidylinositol kinase inhibitors | CUROVIR AB (SE) | 2021-05-11 | — | — | US | disclosed |
| US-11001587-B2 | Substituted indazoles as phosphatidylinositol kinase inhibitors | CUROVIR AB (SE) | 2021-05-11 | — | — | US | disclosed |
| US-20200031833-A1 | HETEROAROMATIC COMPOUNDS USEFUL IN THERAPY | CUROVIR AB (SE) | 2020-01-30 | — | — | US | disclosed |
| US-20200031833-A1 | HETEROAROMATIC COMPOUNDS USEFUL IN THERAPY | CUROVIR AB (SE) | 2020-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11001587-B2 | Substituted indazoles as phosphatidylinositol kinase inhibitors | PIKFYVE, PI4KA, PIP4K2B | PI4KB 6/4885KDM4E 3032/4885SMN1; SMN2 2151/4885 |
| US-20200031833-A1 | HETEROAROMATIC COMPOUNDS USEFUL IN THERAPY | BECN1, SQSTM1, TFEB | PI4KB 630/4885KDM4E 4130/4885SMN1; SMN2 920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.